Abstract
11 C-Methionine PET provides unique information in the diagnosis of brain tumours. In comparison to 18 F-FDG PET, due to low uptake in normal brain tissue and inflammatory cells, high contrast is obtained for the diagnosis of low-grade tumours and differentiation against inflammatory changes. When compared to MRT, one major advantage of PET with radioactive labelled amino acids is the realistic reflection of the biologically active part of the tumour. This part is often larger than the area of blood brain barrier disturbance as outlined by the enhancement of contrast media in MRT - and smaller than the tumour oedema as shown in the T2 weighted images. Hence, 11 C-Methionine PET is able to contribute substantially in planning of surgical or radiation therapy. In the evaluation of treatment results, especially the quantitative information with regard to regional extension and intensity of elevated amino acid uptake can be crucial to establish the necessity and size for re-intervention as the case may be. For clinical research, radio-labelled amino acids can be used - due to their prognostic potential - as a tool to select biologically comparable tumours for a prospective study. From the patients perspective, 11 C-Methionine PET is a simple, non-invasive procedure, with a relatively low radiation exposure.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
